You are here

Safety, Pharmacokinetics Trial of BlockAide/CR To Begin

SAN DIEGO, April 15, 2004 – ADVENTRX Pharmaceuticals, Inc. (OTCBB: AVRX) announced today that the Investigational New Drug Application (IND) for its HIV-1 entry inhibitor, BlockAide/CR™, received FDA clearance to begin a Phase Ib/IIa human clinical trial. The trial will assess safety, pharmacokinetics and effect on viral load of BlockAide/CR in HIV-1 positive individuals with evidence of increasing viral load despite treatment with other antiretroviral therapy.

"We were encouraged by preclinical studies that showed BlockAide/CR was safe and active against multiple HIV strains," commented Joan M. Robbins, Ph.D., ADVENTRX Chief Technical Officer. "With toxicities associated with current treatment regimens and viral resistance continuing to be a major problem, there is an indisputable need for alternative treatment options. We are hopeful that BlockAide/CR can address these issues."

BlockAide/CR is a synthetic 15 amino acid peptide, which mimics a portion of HIV-1 that is responsible for entry into the immune system cell. The BlockAide/CR peptide binds to immune system cells, preventing co-receptor interaction necessary for HIV fusion and entry. Since BlockAide/CR binds to immune system cells to inhibit viral entry rather than binding directly to HIV, BlockAide/CR may be less susceptible to problems with viral resistance associated with other viral entry inhibitors and HAART (highly active antiretroviral therapy) drugs.

The clinical study is planned to be conducted at the VA San Diego Healthcare System under the direction of David J. Looney, M.D., Principal Investigator, Veterans Medical Research Foundation. Drug safety and effects on HIV viral load and CD4+ T cell count will be determined.

Source: ADVENTRX Pharmaceuticals, Inc.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug